{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:04:03Z","timestamp":1790208243299,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,5,30]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Immunoglobulin G\n                      <jats:sub>4<\/jats:sub>\n                      (IgG\n                      <jats:sub>4<\/jats:sub>\n                      ) related disease (RD) is a multisystem, immunologically mediated disease discovered within the last two decades. Within the nervous system, a broad range of both central and peripheral nervous system involvement has been reported. We aimed to systematically review the neurological manifestations of IgG\n                      <jats:sub>4<\/jats:sub>\n                      -RD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      To identify the clinical presentation, radiological findings, diagnostic methods, treatment and outcomes for neurological manifestations of IgG\n                      <jats:sub>4<\/jats:sub>\n                      -RD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We systematically reviewed the literature to identify all reports of neurological manifestations of IgG\n                      <jats:sub>4<\/jats:sub>\n                      -RD. Data on neurological manifestations, non-neurological manifestations, clinical presentation, radiological findings, diagnostic methods, treatment modalities and outcomes were extracted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 393 cases from 297 publications meeting the inclusion criteria. Hypertrophic pachymeningitis, IgG\n                      <jats:sub>4<\/jats:sub>\n                      -related orbital disease and hypophysitis are the most common neurological manifestations of IgG\n                      <jats:sub>4<\/jats:sub>\n                      -RD. Diagnostic evaluation involves testing for concomitant non-neurological manifestations, an MRI with gadolinium contrast, measurement of serum IgG\n                      <jats:sub>4<\/jats:sub>\n                      levels and a biopsy with specific staining for IgG\n                      <jats:sub>4<\/jats:sub>\n                      positive plasma cells. Treatment with corticosteroids leads to favourable outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      IgG\n                      <jats:sub>4<\/jats:sub>\n                      -RD is an emerging neurological disease that can manifest in multiple ways within the nervous system. It is important to recognise as treatment is often successful.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2025-336230","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T18:45:17Z","timestamp":1750013117000},"page":"1109-1116","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Neurological manifestations of immunoglobulin G\n                    <sub>4<\/sub>\n                    related disease: a systematic review of 393 cases"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-0758","authenticated-orcid":false,"given":"Yau Zane Justin","family":"Ng","sequence":"first","affiliation":[{"name":"Neurology, Royal Hobart Hospital, Hobart, Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scarlett","family":"Bowen","sequence":"additional","affiliation":[{"name":"Royal Hobart Hospital, Hobart, Tasmania, Australia"},{"name":"Neurology, St Vincent\u2019s Hospital Melbourne, Fitzroy, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Phillips","sequence":"additional","affiliation":[{"name":"Royal Hobart Hospital, Hobart, Tasmania, Australia"},{"name":"Box Hill Hospital, Box Hill, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugil","family":"Rajasekaran","sequence":"additional","affiliation":[{"name":"Radiology, Royal Hobart Hospital, Hobart, Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Sheng","family":"Lu","sequence":"additional","affiliation":[{"name":"Radiology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-0070","authenticated-orcid":false,"given":"Bruce V","family":"Taylor","sequence":"additional","affiliation":[{"name":"Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"2026081401350748000_96.11.1109.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223950"},{"key":"2026081401350748000_96.11.1109.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev203"},{"key":"2026081401350748000_96.11.1109.3","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1859710"},{"key":"2026081401350748000_96.11.1109.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30471-4"},{"key":"2026081401350748000_96.11.1109.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0500-7"},{"key":"2026081401350748000_96.11.1109.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1104650"},{"key":"2026081401350748000_96.11.1109.7","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-017-0450-9","article-title":"Neurological Manifestations of IgG4-Related Disease","volume":"19","author":"Baptista","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"2026081401350748000_96.11.1109.8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamaneurol.2024.3947","article-title":"Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis: A Systematic Review","volume":"82","author":"Terrim","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026081401350748000_96.11.1109.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2021.03.054"},{"key":"2026081401350748000_96.11.1109.10","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-015-0530-4","article-title":"IgG4-Related Ophthalmic Disease: Pooling of Published Cases and Literature Review","volume":"15","author":"Wu","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026081401350748000_96.11.1109.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2026081401350748000_96.11.1109.12","doi-asserted-by":"publisher","DOI":"10.1159\/000525908"},{"key":"2026081401350748000_96.11.1109.13","doi-asserted-by":"publisher","DOI":"10.4103\/aian.AIAN_283_18"},{"key":"2026081401350748000_96.11.1109.14","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-018-1027-4"},{"key":"2026081401350748000_96.11.1109.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268943"},{"key":"2026081401350748000_96.11.1109.16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003785","article-title":"Diagnostic Value of Serum IgG4 for IgG4-Related Disease","volume":"95","author":"Hao","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026081401350748000_96.11.1109.17","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000568","article-title":"Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review","volume":"6","author":"Levraut","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026081401350748000_96.11.1109.18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003498","article-title":"Diagnostic utility of serum IgG4 level in IgG4-related diseases: a comprehensive systematic review and meta-analysis","volume":"9","author":"Chang","year":"2023","journal-title":"RMD Open"},{"key":"2026081401350748000_96.11.1109.19","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.177"},{"key":"2026081401350748000_96.11.1109.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.39132"},{"key":"2026081401350748000_96.11.1109.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1567-2"},{"key":"2026081401350748000_96.11.1109.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28405-x","article-title":"Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study","volume":"8","author":"Shirakashi","year":"2018","journal-title":"Sci Rep"},{"key":"2026081401350748000_96.11.1109.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PLoS One"},{"key":"2026081401350748000_96.11.1109.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605"},{"key":"2026081401350748000_96.11.1109.25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-06520-5","article-title":"Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids","volume":"7","author":"Yunyun","year":"2017","journal-title":"Sci Rep"},{"key":"2026081401350748000_96.11.1109.26","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkae020","article-title":"Current and future advances in practice: IgG4-related disease","volume":"8","author":"Wallace","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"2026081401350748000_96.11.1109.27","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12942"},{"key":"2026081401350748000_96.11.1109.28","doi-asserted-by":"publisher","DOI":"10.1177\/1971400918806323"},{"key":"2026081401350748000_96.11.1109.29","doi-asserted-by":"crossref","unstructured":"Kikuchi N , Hatanaka S , Kubo T , et al . Characteristic TARC\/CCL17 expression in the salivary gland of IgG4-related disease: potential diagnostic utility and insights into pathogenesis. Immunol Med 2025;1\u20137. doi:10.1080\/25785826.2025.2460910","DOI":"10.1080\/25785826.2025.2460910"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-336230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:35:28Z","timestamp":1786696528000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-336230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jnnp-2025-336230"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-336230","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]}}}